Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs [Yahoo! Finance]
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: Yahoo! Finance
Executive Officer Michael Metzger reiterated that Syndax Pharmaceuticals (NASDAQ:SNDX) started 2026 on a strong footing, going by the commercial performance of two key marketed products. In addition, the company is making significant progress on clinical and lifecycle milestones. Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs The company generated $125 million in annual net sales for Revuforj and $152 million for Niktimvo in the first 11 months. Consequently, the products are showing quarter-over-quarter sales growth. Revuforj's revenue growth is driven by continued penetration in its labeled indication for KMT2A-rearranged acute myeloid leukemia. In addition, the company is staring at a tremendous opportunity with Niktimvo in chronic GVHD, targeting 6,500 patients that could expand to about 17,000. Consequently, the company could generate up to $1 billion in third-line plus sales. Syndax has a strategic collaboration with Incyte
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Syndax Pharmaceuticals (SNDX) had its price target raised by Citigroup Inc. from $51.00 to $57.00. They now have a "buy" rating on the stock.MarketBeat
- Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? [Yahoo! Finance]Yahoo! Finance
- Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Syndax Pharmaceuticals (SNDX) was given a new $45.00 price target by Stifel Nicolaus.MarketBeat
SNDX
Earnings
- 2/26/26 - Miss
SNDX
Sec Filings
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- SNDX's page on the SEC website